I-domain-antigen conjugate (IDAC) for delivering antigenic peptides to apc: Synthesis, characterization, and in vivo EAE suppression

Bioconjugate Chemistry

Volumn 23, Issue 3, 2012, Pages 509-517

  Manikwar, Prakash ^a   Büyüktimkin, Barlas ^a   Kiptoo, Paul ^a   Badawi, Ahmed H ^a   Galeva, Nadezhda A ^b   Williams, Todd D ^b   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIGENS;

ANTIGEN CONJUGATE; ANTIGEN PRESENTING CELLS; ANTIGENIC PEPTIDES; BLOCKINGS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGICAL SYNAPSE; IN-VIVO; MICE MODELS; SYNTHESISED; VIVO EFFICACIES;

PEPTIDES;

ANTIGEN; I DOMAIN ANTIGEN CONJUGATE; INTERCELLULAR ADHESION MOLECULE 1; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALEIMIDE; PEPTIDE DERIVATIVE; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CIRCULAR DICHROISM; CONJUGATE; CONTROLLED STUDY; DERIVATIZATION; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; IMMUNE SYSTEM; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE;

EID: 84858724328     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200580j     Document Type: Article

References (27)

1. Schwartz, R. H. (2003) T cell anergy Annu. Rev. Immunol. 21, 305-334 (Pubitemid 37174534)
2. Salomon, B. and Bluestone, J. A. (1998) LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production J. Immunol. 161, 5138-5142 (Pubitemid 28519069)
3. Kobayashi, N., Kiptoo, P., Kobayashi, H., Ridwan, R., Brocke, S., and Siahaan, T. J. (2008) Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor Clin. Immunol. 129, 69-79
4. Kobayashi, N., Kobayashi, H., Gu, L., Malefyt, T., and Siahaan, T. J. (2007) Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor J. Pharmacol. Exp. Ther. 322, 879-886 (Pubitemid 47105795)
5. Manikwar, P., Kiptoo, P., Badawi, A. H., Buyuktimkin, B., and Siahaan, T. J. (2011) Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Med. Res. Rev. [Online early access] March 23.
6. Murray, J. S., Oney, S., Page, J. E., Kratochvil-Stava, A., Hu, Y., Makagiansar, I. T., Brown, J. C., Kobayashi, N., and Siahaan, T. J. (2007) Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation Chem. Biol. Drug Des. 70, 227-236 (Pubitemid 47305400)
7. Ridwan, R., Kiptoo, P., Kobayashi, N., Weir, S., Hughes, M., Williams, T., Soegianto, R., and Siahaan, T. J. (2010) Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics J. Pharmacol. Exp. Ther. 332, 1136-1145
8. Zhao, H., Kiptoo, P., Williams, T. D., Siahaan, T. J., and Topp, E. M. (2010) Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model J. Controlled Release 141, 145-152
9. Shimaoka, M., Xiao, T., Liu, J. H., Yang, Y., Dong, Y., Jun, C. D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., Wang, J. H., and Springer, T. A. (2003) Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation Cell 112, 99-111 (Pubitemid 36106422)
10. Manikwar, P., Zimmerman, T., Blanco, F. J., Williams, T. D., and Siahaan, T. J. (2011) Rapid identification of fluorochrome modification sites in proteins by LC ESI-Q-TOF mass spectrometry Bioconjugate Chem. 22, 1330-1336
11. Zimmerman, T., Oyarzabal, J., Sebastian, E. S., Majumdar, S., Tejo, B. A., Siahaan, T. J., and Blanco, F. J. (2007) ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization Chem. Biol. Drug Des. 70, 347-353 (Pubitemid 47537691)
12. Speicher, K., Kolbas, O., Harper, S., and Speicher, D. (2000) Systematic analysis of peptide recoveries from in-gel digestions for protein identifications in proteome studies J. Biomol. Technol. 11, 74-86
13. Ikehata, K., Duzhak, T. G., Galeva, N. A., Ji, T., Koen, Y. M., and Hanzlik, R. P. (2008) Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo Chem. Res. Toxicol. 21, 1432-1442
14. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search Anal. Chem. 74, 5383-5392 (Pubitemid 35215372)
15. Partis, M. D., Griffiths, D. G., Roberts, G. C., and Beechey, R. B. (1983) Cross-linking of protein by omega-maleimido alkanoyl N-hydroxysuccinimido esters J. Protein Chem. 2, 263-277 (Pubitemid 14200049)
16. Tan, C. S. and Koralnik, I. J. (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis Lancet Neurol. 9, 425-437
17. Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., and Bennett, C. L. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project Lancet Oncol. 10, 816-824
18. Pugashetti, R. and Koo, J. (2009) Efalizumab discontinuation: a practical strategy J. Dermatol. Treat. 20, 132-136
19. Blanchfield, J. L. and Mannie, M. D. (2010) A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC J. Leukoc. Biol. 87, 509-521
20. Ni, J., Zhu, Y. N., Zhong, X. G., Ding, Y., Hou, L. F., Tong, X. K., Tang, W., Ono, S., Yang, Y. F., and Zuo, J. P. (2009) The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function Br. J. Pharmacol. 158, 2046-2056
21. Wang, C., Gold, B. G., Kaler, L. J., Yu, X., Afentoulis, M. E., Burrows, G. G., Vandenbark, A. A., Bourdette, D. N., and Offner, H. (2006) Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE J. Neurochem. 98, 1817-1827 (Pubitemid 44313640)
22. Falk, K., Rotzschke, O., Santambrogio, L., Dorf, M. E., Brosnan, C., and Strominger, J. L. (2000) Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides J. Exp. Med. 191, 717-730
23. Luca, M. E., Kel, J. M., van Rijs, W., Wouter Drijfhout, J., Koning, F., and Nagelkerken, L. (2005) Mannosylated PLP(139-151) induces peptide-specific tolerance to experimental autoimmune encephalomyelitis J. Neuroimmunol. 160, 178-187 (Pubitemid 40248607)
24. Meiron, M., Zohar, Y., Anunu, R., Wildbaum, G., and Karin, N. (2008) CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells J. Exp. Med. 205, 2643-2655
25. Manikwar, P., Tejo, B. A., Shinogle, H., Moore, D. S., Zimmerman, T., Blanco, F., and Siahaan, T. J. (2011) Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes Theranostics 1, 277-289
26. Jin, M., Song, G., Carman, C. V., Kim, Y. S., Astrof, N. S., Shimaoka, M., Wittrup, D. K., and Springer, T. A. (2006) Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity Proc. Natl. Acad. Sci. U.S.A. 103, 5758-5763
27. Badawi, A. H., Kiptoo, P., Wang, W. T., Choi, I. Y., Lee, P., Vines, C. M., and Siahaan, T. J. (2011) Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor Neuropharmacology 62, 1874-1881